MedTrace Logo

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT04445701 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-08-22

No results posted yet for this study

Summary

Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed/refractory multiple myeloma (MM).

Conditions

Interventions

DRUG

AO-176

Humanized monoclonal antibody (mAb) targeting CD47

DRUG

AO-176 + Dex

Humanized mAb targeting CD47 plus dexamethasone

DRUG

AO-176 + Dex + Bort

Humanized mAb targeting CD47 plus dexamethasone plus bortezomib

Sponsors & Collaborators

  • Arch Oncology

    lead INDUSTRY

Principal Investigators

  • Ben Oshrine, MD · Sr Medical Director, Arch Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2022-08-05
Completion
2022-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04445701 on ClinicalTrials.gov